KPTI (Karyopharm Therapeutics) Moat Score: 4/10 (As of Jul. 05, 2026)


KPTI Karyopharm Therapeutics Inc KPTI
52 GF Score
Price $9.60
GF Value $6.34
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Karyopharm Therapeutics Moat Score?

Karyopharm Therapeutics KPTI +0.63% 52 Moat Score is 4 as of Jul. 05, 2026. GuruFocus rates KPTI with a GF Score™ of 52/100 and a GF Value™ of $6.34 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,395 Biotechnology companies, Karyopharm Therapeutics ranks better than 88.75% on this metric.

Karyopharm Therapeutics has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Karyopharm Therapeutics has Narrow Moat: Karyopharm Therapeutics Inc has a discernible moat due to its proprietary drug development and some valuable patents. However, the competitive landscape in pharmaceuticals and the need for continuous innovation limit the strength of its moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Karyopharm Therapeutics might have Narrow Moat - Discernible but modest moat.

Karyopharm Therapeutics  (NAS:KPTI) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Karyopharm Therapeutics Moat Score Related Terms

KPTI vs CHRS, TARA, CNTN: Moat Score Comparison

For the Biotechnology subindustry, Karyopharm Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Karyopharm Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Karyopharm Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Karyopharm Therapeutics's Moat Score falls into.


KPTI
52GF Score
Karyopharm Therapeutics Inc KPTI
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Karyopharm Therapeutics (KPTI) has a Moat Score of 4 as of Jul. 05, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Karyopharm Therapeutics ranks #157 out of 1395 companies in the Biotechnology industry, placing it in the top 11.3%.
Is Karyopharm Therapeutics' Moat Score too high?
Karyopharm Therapeutics' current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Karyopharm Therapeutics' value of 4 is 100% above this industry median. Based on the distribution chart, Karyopharm Therapeutics ranks #157 out of 1395 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Karyopharm Therapeutics has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Karyopharm Therapeutics' Moat Score compare to CHRS and TARA?
According to the Biotechnology industry distribution chart, Karyopharm Therapeutics ranks #157 out of 1395 companies for Moat Score. This places Karyopharm Therapeutics in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Karyopharm Therapeutics' value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Karyopharm Therapeutics's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Karyopharm Therapeutics's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Karyopharm Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Karyopharm Therapeutics (KPTI) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.34, compared to a current price of $9.60 — trading 51.4% above its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Karyopharm Therapeutics' overall GF Score™ is 52/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Karyopharm Therapeutics (KPTI), the current Moat Score is 4 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Karyopharm Therapeutics (KPTI) Overvalued in 2026?

Based on GuruFocus' analysis, Karyopharm Therapeutics stock appears to be overvalued. The current stock price of $9.60 is trading 51.4% above its estimated GF Value™ of $6.34. GuruFocus considers Karyopharm Therapeutics to be Significantly Overvalued.

Key valuation signals for KPTI:

  • Moat Score: 4
  • GF Value™: $6.34 vs. price of $9.60 (51.4% above fair value)
  • GF Score™: 52/100 with 8 warning signs
  • Industry Position: 100% above the Biotechnology median (#157 of 1395)

No single metric tells the full story. See the KPTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Karyopharm Therapeutics Business Description

Other Exchanges 25K0:Germany
Address 85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
52GF Score

Get the complete analysis for KPTI

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.60
Price
$6.34
GF Value